Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study

BACKGROUND: Prostate cancer that progresses after enzalutamide treatment is poorly responsive to further antiandrogen therapy, and paradoxically, rapid cycling between high and low serum testosterone concentrations (bipolar androgen therapy [BAT]) in this setting might induce tumour responses. We ai...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Lancet Oncol
Hoofdauteurs: Teply, Benjamin A, Wang, Hao, Luber, Brandon, Sullivan, Rana, Rifkind, Irina, Bruns, Ashley, Spitz, Avery, DeCarli, Morgan, Sinibaldi, Victoria, Pratz, Caroline F, Lu, Changxue, Silberstein, John L, Luo, Jun, Schweizer, Michael T, Drake, Charles G, Carducci, Michael A, Paller, Channing J, Antonarakis, Emmanuel S, Eisenberger, Mario A, Denmeade, Samuel R
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2017
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5875180/
https://ncbi.nlm.nih.gov/pubmed/29248236
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30906-3
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items